Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 5/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | MTOR | P42345 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1820120 | 0.97 | HDAC8 (0.58) | HDAC8FFAR1GRM5PIK3CAMTOR | |
| SCHEMBL9610040 | 0.91 | MAPT (0.53) | HDAC8FFAR1GRM5PIK3CAMTOR | |
| SCHEMBL17224548 | 0.89 | APP (0.63) | HDAC8FFAR1GRM5PIK3CAMTOR | |
| SCHEMBL13219274 | 0.89 | MAPT (0.58) | HDAC8FFAR1GRM5PIK3CAMTOR | |
| SCHEMBL13907339 | 0.88 | HDAC8 (0.50) | HDAC8FFAR1GRM5PIK3CAMTOR | |
| Methyl Alcohol SCHEMBL28280712 | 0.88 | GRM5 (0.52) | HDAC8FFAR1GRM5PIK3CAMTOR | |
| SCHEMBL13907329 | 0.88 | HDAC8 (0.50) | HDAC8FFAR1GRM5PIK3CAMTOR | |
| SCHEMBL14061509 | 0.87 | CYP11B2 (0.45) | HDAC8FFAR1GRM5 | |
| SCHEMBL2527326 | 0.87 | USP2 (0.45) | HDAC8FFAR1GRM5 | |
| SCHEMBL2526701 | 0.87 | CYP19A1 (0.48) | HDAC8FFAR1GRM5LMNACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636634-B2 | Fluorinated MOF materials having rectangular channels, method of synthesizing MOF materials and methods of using MOF materials including for CO2 capture | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2026-05-26 | — | — | US | claimed |
| US-20240316530-A1 | FLUORINATED MOF MATERIALS HAVING RECTANGULAR CHANNELS, METHOD OF SYNTHESIZING MOF MATERIALS AND METHODS OF USING MOF MATERIALS INCLUDING FOR CO2 CAPTURE | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2024-09-26 | — | — | US | claimed |
| WO-2024196666-A1 | FLUORINATED MOF MATERIALS HAVING RECTANGULAR CHANNELS, METHOD OF SYNTHESIZING MOF MATERIALS AND METHODS OF USING MOF MATERIALS INCLUDING FOR CO2 CAPTURE | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2024-09-26 | — | — | WO | claimed |
| CN-116589508-A | Rectangular molecular macrocyclic compound based on half-sandwich rhodium building unit, and preparation method and application thereof | 洛阳师范学院 | 2023-08-15 | — | — | CN | claimed |
| US-20070026078-A1 | Pharmaceutical co-crystal compositions | TRANSFORM PHARMACEUTICALS, INC. (US) | 2007-02-01 | — | — | US | claimed |
| US-12636634-B2 | Fluorinated MOF materials having rectangular channels, method of synthesizing MOF materials and methods of using MOF materials including for CO2 capture | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2026-05-26 | — | — | US | disclosed |
| US-20240316530-A1 | FLUORINATED MOF MATERIALS HAVING RECTANGULAR CHANNELS, METHOD OF SYNTHESIZING MOF MATERIALS AND METHODS OF USING MOF MATERIALS INCLUDING FOR CO2 CAPTURE | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2024-09-26 | — | — | US | disclosed |
| WO-2024196666-A1 | FLUORINATED MOF MATERIALS HAVING RECTANGULAR CHANNELS, METHOD OF SYNTHESIZING MOF MATERIALS AND METHODS OF USING MOF MATERIALS INCLUDING FOR CO2 CAPTURE | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2024-09-26 | — | — | WO | disclosed |
| CN-116589508-A | Rectangular molecular macrocyclic compound based on half-sandwich rhodium building unit, and preparation method and application thereof | 洛阳师范学院 | 2023-08-15 | — | — | CN | disclosed |
| US-20230143425-A1 | IMPROVEMENTS RELATED TO SORBENT MEDIA | GENESIS SYSTEMS LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230143425-A1 | IMPROVEMENTS RELATED TO SORBENT MEDIA | GENESIS SYSTEMS LLC | 2023-05-11 | — | — | US | disclosed |
| EP-3411140-B1 | METHOD FOR SEPARATING ACETYLENE FROM A GAS MIXTURE | UNIV LIMERICK (IE) | 2021-08-18 | — | — | EP | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7825248-B2 | Synthetic nanopores for DNA sequencing | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2010-11-02 | — | — | US | disclosed |
| US-7767213-B2 | Synthetic nanopores for DNA sequencing | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090131669-A1 | Synthetic Nanopores for DNA Sequencing | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131642-A1 | Synthetic Nanopores for DNA Sequencing | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS PREPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2009-05-21 | — | — | US | disclosed |
| US-7504505-B2 | Synthetic nanopores for DNA sequencing | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2009-03-17 | — | — | US | disclosed |
| US-20070059356-A1 | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen | REGENTS OF THE UNIVERSITY OF MICHIGAN, THE | 2007-03-15 | — | — | US | disclosed |
| US-20070026078-A1 | Pharmaceutical co-crystal compositions | TRANSFORM PHARMACEUTICALS, INC. (US) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131669-A1 | Synthetic Nanopores for DNA Sequencing | POLN, POLRMT, PARN | HDAC8 2801/4885FFAR1 4737/4885GRM5 2355/4885 |
| US-12636634-B2 | Fluorinated MOF materials having rectangular channels, method of synthesizing MOF materials and methods of using MOF materials including for CO2 capture | MLX, BMP4, F13B | HDAC8 2881/4885FFAR1 1584/4885GRM5 1915/4885 |
| US-20090131642-A1 | Synthetic Nanopores for DNA Sequencing | POLN, POLRMT, PARN | HDAC8 2801/4885FFAR1 4737/4885GRM5 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.